<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Gilada Finance &amp; Investments Ltd. (GILADAFINS) — Tipsheet</title>
    <link>https://tipsheet.markets/company/giladafins/</link>
    <atom:link href="https://tipsheet.markets/company/giladafins/feed.xml" rel="self" type="application/rss+xml" />
    <description>Every Tipsheet Editorial note covering Gilada Finance &amp; Investments Ltd. (GILADAFINS), newest first. Grounded in BSE/NSE primary-source filings.</description>
    <language>en-in</language>
    <lastBuildDate>Mon, 06 Jul 2026 10:22:47 GMT</lastBuildDate>
    <item>
      <title>Gilada Finance forms JV with Harley of London India</title>
      <link>https://tipsheet.markets/giladafins-gilada-finance-forms-jv-with-harley-of-london-india-110158/</link>
      <guid isPermaLink="true">https://tipsheet.markets/giladafins-gilada-finance-forms-jv-with-harley-of-london-india-110158/</guid>
      <pubDate>Fri, 19 Jun 2026 16:18:24 GMT</pubDate>
      <description>Partnership covers healthcare, wellness, lifestyle, and financial services under the HOLNESS brand. Board also approves ₹5 lakh NCD at 12.25%.</description>
      <content:encoded><![CDATA[<p><em>Partnership covers healthcare, wellness, lifestyle, and financial services under the HOLNESS brand. Board also approves ₹5 lakh NCD at 12.25%.</em></p>
<h3>What’s new</h3><ul><li>Board approved JV with Harley of London India for HOLNESS ecosystem.</li><li>Allotted five NCDs worth ₹5 lakhs at 12.25% for two years.</li><li>Appointed Anand Boob &amp; Associates as internal auditor.</li></ul>
<h3>Why it matters</h3><p>For a nano-cap with ₹19 cr market cap and flat net profit, the JV provides a strategic direction but lacks financial details. The partnership could open new revenue lines, but execution remains the key risk.</p>
<h3>What we’re watching</h3><ul><li>Whether the JV leads to any revenue or capital infusion.</li><li>Any detailed agreement terms in future filings.</li><li>Impact on the company's core stock broking business.</li></ul>
<h3>The full read</h3><p>Gilada Finance &amp; Investments has formally entered a joint venture with Harley of London India, sponsored by Delamore &amp; Owl Group, to develop the HOLNESS ecosystem spanning healthcare, wellness, lifestyle, and financial services. The board also approved a <strong>₹5 lakh</strong> NCD allotment at <strong>12.25%</strong> and appointed a new internal auditor. For a company with a <strong>₹19 crore</strong> market cap and net profit of <strong>₹0 crore</strong> in the latest quarter, any strategic move is notable. However, the JV announcement carries no financial terms or investment commitment, leaving the actual scope unclear. The small NCD size suggests limited immediate capital needs. The real test will be whether this partnership translates into revenue growth beyond the core stock broking business.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=538788&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=GILADAFINS">NSE</a></p>]]></content:encoded>
      <category>Other</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
    <item>
      <title>Gilada Finance board to weigh JV, NCD allotment</title>
      <link>https://tipsheet.markets/giladafins-gilada-finance-board-to-weigh-jv-ncd-allotment-108541/</link>
      <guid isPermaLink="true">https://tipsheet.markets/giladafins-gilada-finance-board-to-weigh-jv-ncd-allotment-108541/</guid>
      <pubDate>Mon, 15 Jun 2026 15:29:14 GMT</pubDate>
      <description>Nano-cap firm with ₹17 cr market cap mulls strategic move; no counterparty or investment details disclosed yet.</description>
      <content:encoded><![CDATA[<p><em>Nano-cap firm with ₹17 cr market cap mulls strategic move; no counterparty or investment details disclosed yet.</em></p>
<h3>What’s new</h3><ul><li>Board meeting called to consider a strategic joint venture.</li><li>NCD allotment also on the agenda, amount unspecified.</li><li>Filing provides no counterparty, investment size, or terms.</li></ul>
<h3>Why it matters</h3><p>For a company with trailing PAT down <strong>14.5%</strong> and ROE of <strong>8.9%</strong>, a JV could be a pivot. But the total absence of detail makes this a placeholder. The market knows nothing about execution or scale.</p>
<h3>What we’re watching</h3><ul><li>Counterparty disclosure and credibility.</li><li>Investment size relative to the ₹17 cr market cap.</li><li>NCD terms. Debt or convertible?</li></ul>
<h3>The full read</h3><p>Gilada Finance's board will meet to weigh a strategic joint venture and an NCD allotment. That is all the filing says. For a company with a market cap of <strong>₹17 cr</strong>, trailing revenue growth of just <strong>4.8%</strong>, and a <strong>14.5%</strong> drop in PAT, a JV could be a necessary catalyst. But the filing offers zero details. No counterparty, no investment size, no terms. The NCD allotment, similarly unspecified, hints at a capital raise but nothing more. This is a preliminary disclosure, not an actionable event. What matters now is what comes after the board meeting: the counterparty's standing, the quantum of investment relative to the company's size, and the debt terms. Until then, the story is a placeholder.</p>
<p>Primary source: <a href="https://www.bseindia.com/corporates/ann.html?scrip=538788&dur=A">BSE</a> · <a href="https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=GILADAFINS">NSE</a></p>]]></content:encoded>
      <category>Other</category>
      <dc:creator>Tipsheet Editorial</dc:creator>
    </item>
  </channel>
</rss>